

Figure 1




Figure 2







Figure 3

Immunolabeling for α -SMA



control



cCAF-treated








Figure 4

bioRxiv preprint doi: <https://doi.org/10.1101/000000>; this version posted January 1, 2014. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.




Figure 5




Figure 6

bioRxiv preprint doi: <https://doi.org/10.1101/000000>; this version posted January 1, 2015. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.






Figure 7




control (day 0)



cCAF (day 0)



control (day 3)



cCAF (day 3)





Figure 8




Figure 9

Summary of cCAF/Peptide effects on cCXCR1




Figure 11